Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: A systematic review

Acta Tropica

Volumn 135, Issue 1, 2014, Pages 86-95

  Keating, Joseph ^a   Yukich, Joshua O ^a   Mollenkopf, Sarah ^a   Tediosi, Fabrizio ^b,c,d  

^a TULANE UNIVERSITY   (United States)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d BOCCONI UNIVERSITY   (Italy)

Author keywords

Control; Cost; Lymphatic filariasis; Onchocerciasis; Treatment

Indexed keywords

COST ANALYSIS; DISEASE CONTROL; DISEASE TREATMENT; FILARIASIS; MEDICINE; ONCHOCERCIASIS; SYNERGISM;

COST BENEFIT ANALYSIS; ECONOMICS; ELEPHANTIASIS, FILARIAL; HEALTH CARE COST; HUMAN; INSECT CONTROL; ONCHOCERCIASIS;

COST-BENEFIT ANALYSIS; ELEPHANTIASIS, FILARIAL; HEALTH CARE COSTS; HUMANS; INSECT CONTROL; ONCHOCERCIASIS;

EID: 84898982764     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2014.03.017     Document Type: Review

References (101)

1. Addiss D., Brady M. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J. 2007, 6:2.
2. Ahorlu C.K., Dunyo S.K., Asamoah G., Simonsen P.E. Consequences of hydrocele and the benefits of hydrocelectomy: a qualitative study in lymphatic filariasis endemic communities on the coast of Ghana. Acta Trop. 2001, 80:215-221.
3. Amazigo U., Noma M., Boatin B.A., Etya'Alés D.E., Sékétéli A., Dadzie K.Y. Delivery systems and cost recovery in Mectizan treatment for onchocerciasis. Ann. Trop. Med. Parasitol. 1998, 92:23.
4. Ashton R., Kyabayinze D., Opio T., Auma A., Edwards T., Matwale G., Onapa A., Brooker S., Kolaczinski J. The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda. Parasit. Vectors 2011, 4:134.
5. Babu B.V., Mishra S., Mishra S., Swain B.K. Personal-protection measures against mosquitoes: a study of practices and costs in a district, in the Indian state of Orissa, where malaria and lymphatic filariasis are co-endemic. Ann. Trop. Med. Parasitol. 2007, 101:601-609.
6. Babu B.V., Nayak A.N. Treatment costs and work time loss due to episodic adenolymphangitis in lymphatic filariasis patients in rural communities of Orissa, India. Trop. Med. Int. Health 2003, 8:1102-1109.
7. Babu B.V., Nayak A.N., Dhal K., Acharya A.S., Jangid P.K., Mallick G. The economic loss due to treatment costs and work loss to individuals with chronic lymphatic filariasis in rural communities of Orissa, India. Acta Trop. 2002, 82:31-38.
8. Baker M.C., McFarland D.A., Gonzales M., Diaz M.J., Molyneux D.H. The impact of integrating the elimination programme for lymphatic filariasis into primary health care in the Dominican Republic. Int. J. Health Plann. Manage. 2007, 22:337-352.
9. Benton B. Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Ann. Trop. Med. Parasitol. 1998, 92:33.
10. Benton B., Bump J., Sékétéli A., Liese B. Partnership and promise: evolution of the African river-blindness campaigns. Ann. Trop. Med. Parasitol. 2002, 96:5.
11. Benton B., Skinner E.D. Cost-benefits of onchocerciasis control. Acta Leiden. 1990, 59:405-411.
12. Blackburn B.G., Eigege A., Gotau H., Gerlong G., Miri E., Hawley W.A., Mathieu E., Richards F. Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria. Am. J. Trop. Med. Hyg. 2006, 75:650-655.
13. Blanks J., Richards F., Beltrán F., Collins R., Alvarez E., Zea F.G., Bauler B., Cedillos R., Heisler M., Brandling-Bennett D., Baldwin W., Bayona M., Klein R., Jacox M. The Onchocerciasis Elimination Program for the Americas: a history of partnership. Rev. Panam. Salud Publica 1998, 3:367-374.
14. Bockarie M.J., Tavul L., Kastens W., Michael E., Kazura J.W. Impact of untreated bednets on prevalence of Wuchereria bancrofti transmitted by Anopheles farauti in Papua New Guinea. Med. Vet. Entomol. 2002, 16:116-119.
15. Brieger W.R. Implementation and sustainability of Community-Directed Treatment of Onchocerciasis with Ivermectin: A Multicountry Study. Special Programme for Research and Training on Tropical Diseases 2000, UNDP/World Bank/WHO, Geneva.
16. Burkot T., Durrheim D., Melrose W., Speare R., Ichimori K. The argument for integrating vector control with multiple drug administration campaigns to ensure elimination of lymphatic filariasis. Filaria J. 2006, 5:10.
17. Burkot T., Ichimori K. The PacELF programme: will mass drug administration be enough?. Trends Parasitol. 2002, 18:109-115.
18. Chandrasena T.G., Premaratna R., Abeyewickrema W., de Silva N.R. Evaluation of the ICT whole-blood antigen card test to detect infection due to Wuchereria bancrofti in Sri Lanka. Trans. R. Soc. Trop. Med. Hyg. 2002, 96(1):60-63.
19. Chandrasena T.N., Premaratna R., de Silva N. Lymphoedema management knowledge and practices among patients attending filariasis morbidity control clinics in Gampaha District, Sri Lanka. Filaria J. 2004, 3:6.
20. Chu B.K., Hooper P.J., Bradley M.H., McFarland D.A., Ottesen E.A. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl. Trop. Dis. 2010, 4:e708.
21. Coyne P., Berk D. The Mectizan (Ivermectin) Donation Program for Riverblindness as a Paradigm for Pharmaceutical Industry Donation Programs 2001, The World Bank, Washington, DC.
22. Dadzie K.Y. Control of onchocerciasis: challenges for the future. Ann. Trop. Med. Parasitol. 1998, 92:65.
23. Das P.K., Manoharan A., Ramaiah K.D., Balarajan K., Dhanda V. Cost analysis of blood surveys for the detection of microfilaria carriers in rural areas. Natl. Med. J. India 1995, 8:143-144.
24. De Rochars M.B., Direny A.N., Roberts J.M., Addiss D.G., Radday J., Beach M.J., Streit T.G., Dardith D., Lafontant J.G., Lammie P.J. Community-Wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. Am. J. Trop. Med. Hyg. 2004, 71:466-470.
25. De Rochars M.B., Kanjilal S., Direny A.N., Radday J., Lafontant J.G., Mathieu E., Rheingans R.D., Haddix A.C., Streit T.G., Beach M.J., Addiss D.G., Lammie P.J. The Leogane, Haiti Demonstration Project: decreased microfilaremia and program costs after three years of mass drug administration. Am. J. Trop. Med. Hyg. 2005, 73:888-894.
26. Eddleston M., Davidson R., Brent A., Wilkinson R. Oxford Handbook of Tropical Medicine 2011, Oxford University Press, Oxford, UK.
27. Emukah E., Graves P.M., Mosher A.W., Rakers L., Miri E., Chidiebere N., Kenrick N., Josephine O., Njideka O.T., Richards F.O. Abstract Book American Society of Tropical Medicine and Hygiene. 58th Annual Meeting, November 18-22 2009.
28. Emukah E.C., Enyinnaya U., Olaniran N.S., Akpan E.A., Hopkins D.R., Miri E.S., Amazigo U., Okoronkwo C., Stanley A., Rakers L., Richards F.O., Katabarwa M.N. Factors affecting the attrition of community-directed distributors of ivermectin, in an onchocerciasis-control programme in the Imo and Abia states of south-eastern Nigeria. Ann. Trop. Med. Parasitol. 2008, 102:45-51.
29. Evans D., McFarland D., Adamani W., Eigege A., Miri E., Schulz J., Pede E., Umbugadu C., Ogbu-Pearse P., Richards F.O. Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria. Ann. Trop. Med. Parasitol. 2011, 105:537-547.
30. Evans D.B., Gelband H., Vlassoff C. Social and economic factors and the control of lymphatic filariasis: a review. Acta Trop. 1993, 53:1-26.
31. Evans T.G. Socioeconomic consequences of blinding onchocerciasis in west Africa. Bull. World Health Org. 1995, 73.
32. Gasarasi D.B., Premji Z.G., Mujinja P.G.M., Mpembeni R. Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania. Acta Trop. 2000, 75:19-28.
33. Giglioli G., Beadness H.M. Filariasis in British Guiana: some industrial medical problems. Indian J. Malariol. 1960, 14:651-658.
34. Goldman A.S., Brady M.A., Direny A., Desir L., Oscard R., Vely J.-F., Linehan M., Baker M. Costs of integrated mass drug administration for neglected tropical diseases in Haiti. Am. J. Trop. Med. Hyg. 2011, 85:826-833.
35. Goldman A.S., Guisinger V.H., Aikins M., Amarillo M.L.E., Belizario V.Y., Garshong B., Gyapong J., Kabali C., Kamal H.A., Kanjilal S., Kyelem D., Lizardo J., Malecela M., Mubyazi G., Nitièma P.A., Ramzy R.M.R., Streit T.G., Wallace A., Brady M.A., Rheingans R., Ottesen E.A., Haddix A.C. National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl. Trop. Dis. 2007, 1:e67.
36. Gyapong J.O., Gyapong M., Evans D.B., Aikins M.K., Adjei S. The economic burden of lymphatic filariasis in northern Ghana. Ann. Trop. Med. Parasitol. 1996, 90:39-48.
37. Gyapong J.O., Twum-Danso N.A.Y. Editorial: Global elimination of lymphatic filariasis: fact or fantasy?. Trop. Med. Int. Health 2006, 11:125-128.
38. Gyapong M., Gyapong J., Weiss M., Tanner M. The burden of hydrocele on men in Northern Ghana. Acta Trop. 2000, 77:287-294.
39. Gyapong M., Gyapong J.O., Owusu-Banahene G. Community-directed treatment: the way forward to eliminating lymphatic filariasis as a public-health problem in Ghana. Ann. Trop. Med. Parasitol. 2001, 95:77-86.
40. Haddad D., Cross C., Thylefors B., Richards J.F.O., Bush S., Hopkins A.D., Baker S.K. Health care at the end of the road: opportunities from 20 years of partnership in onchocerciasis control. Glob. Public Health 2008, 3:187-196.
41. Haddix A. An Economic Re-evaluation of the African Programme for Onchocerciasis Control 1997, Rollins School of Public Health, Emory University, Atlanta, GA.
42. Homeida M., Braide E., Elhassan E., Amazigo U.V., Liese B., Benton B., Noma M., Etya'Ale D., Dadzie K.Y., Kale O.O., Sékétéli A. APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. Ann. Trop. Med. Parasitol. 2002, 96:93.
43. Hopkins A.D. Challenges for the integration of mass drug administrations against multiple 'neglected tropical diseases'. Ann. Trop. Med. Parasitol. 2009, 103:23-31.
44. Hopkins D.R., Eigege A., Miri E.S., Gontor I., Ogah G., Umaru J., Gwomkudu C.C., Mathai W., Jinadu M., Amadiegwu S., Oyenekan O.K., Korve K., Richards F.O. Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria. Am. J. Trop. Med. Hyg. 2002, 67:266-272.
45. John D.T., Petri W.A., Markell E.K., Voge M. Markell and Voge's Medical Parasitology 2006, Saunders Elsevier.
46. Katabarwa M.N., Habomugisha P., Richards F.O. Implementing community-directed treatment with ivermectin for the control of onchocerciasis in Uganda (1997-2000): an evaluation. Ann. Trop. Med. Parasitol. 2002, 96(1):61-73.
47. Kessel J.F. Disabling effects and control of filariasis. Am. J. Trop. Med. Hyg. 1957, 6:402-414.
48. Kim A., Benton B. Cost-Benefit Analysis of the Onchocerciasis Control Program (OCP) 1995, The World Bank, Washington, DC.
49. Krishnamoorthy K. Estimated costs of acute adenolymphangitis to patients with chronic manifestations of bancroftian filariasis in India. Indian J. Public Health 1999, 43:58-63.
50. Krishnamoorthy K., Rajendran R., Sunish I.P., Reuben R. Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis. Ann. Trop. Med. Parasitol. 2002, 96:77.
51. Kron M., Walker E., Hernandez L., Torres E., Libranda-Ramirez B. Lymphatic filariasis in the Philippines. Parasitol. Today 2000, 16:329-333.
52. Lammie P.J., Fenwick A., Utzinger J. A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol. 2006, 22:313-321.
53. London Declaration to Control NTDs From Promises to Progress: The 1st Annual Report on the London Declaration on NTDs 2013, www.unitingToCombatNTDs.org.
54. Maxwell C.A., Curtis C.F., Haji H., Kisumku S., Thalib A.I., Yahya S.A. Control of bancroftian filariasis by integrating therapy with vector control using polystyrene beads in wet pit latrines. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:709-714.
55. Mbanefo E.C., Eneanya C.I., Nwaorgu O.C., Oguoma V.M., Otiji M.O., Ogolo B.A. Onchocerciasis in Anambra State, Southeast Nigeria: clinical and psychological aspects and sustainability of community directed treatment with ivermectin (CDTI). Postgrad. Med. J. 2010, 86:573-577.
56. McFarland D., Murray J. Review of the Economic Impact of Treatment with Ivermectin for Onchocerciasis 1994, Emory University School of Public Health and the International Health Program Office at the Centers for Disease Control and Prevention, Atlanta, GA.
57. McLaughlin S.I., Radday J., Michel M.C., Addiss D.G., Beach M.J., Lammie P.J., Lammie J., Rheingans R., Lafontant J. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. Am. J. Trop. Med. Hyg. 2003, 68:568-573.
58. Miri E.S. Problems and perspectives onchocerciasis control programme: a case study from Plateau state, Nigeria. Ann. Trop. Med. Parasitol. 1998, 92:121.
59. Mohammed K.A., Molyneux D.H., Albonico M., Rio F. Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme. Trends Parasitol. 2006, 22:340-344.
60. Molyneux D.H., Nantulya V.M. Linking disease control programmes in rural Africa: a pro-poor strategy to reach Abuja targets and millennium development goals. Br. Med. J. 2004, 328:1129-1132.
61. Mutabazi D., Duke B.O.L. Onchocerciasis control in Uganda: how can self-sustaining, community-based treatment with ivermectin be achieved. Ann. Trop. Med. Parasitol. 1998, 92:195.
62. Nanda B., Krishnamoorthy K. Treatment seeking behaviour and costs due to acute and chronic forms of lymphatic filariasis in urban areas in south India. Trop. Med. Int. Health 2003, 8:56-59.
63. Ndyomugyenyi R., Lakwo T., Habomugisha P., Male B. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward. Ann. Trop. Med. Parasitol. 2007, 101:323-333.
64. ® procurement and delivery for onchocerciasis mass drug administration programmes. Acta Trop. 2011, 120(Suppl. 1):S173-S176.
65. Okeibunor J.C., Amuyunzu-Nyamongo M., Onyeneho N.G., Tchounkeu Y.F.L., Manianga C., Kabali A.T., Leak S. Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa. Trop. Med. Int. Health 2011, 16:608-621.
66. Okwero P. The challenge of establishing community directed treatment with Mectizan in Uganda. Ann. Trop. Med. Parasitol. 1998, 92:171.
67. Onwujekwe O., Chima R., Shu E., Okonkwo P. Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences. Health Policy 2002, 62:31-51.
68. Onwujekwe O., Shu E., Onwuameze O., Ndum C., Okonkwo P. Onchocerciasis control in Nigeria: will households be able to afford community-directed treatment with ivermectin?. Acta Trop. 2001, 80:277-281.
69. Onwujekwe O.E., Shu E.N., Nwagbo D., Akpala C.O., Okonkwo P.O. Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis-endemic communities in Nigeria. Trop. Med. Int. Health 1998, 3:802-808.
70. Onwujekwe O.E., Shu E.N., Okonkwo P.O. Willingness to pay for the maintenance of equity in a local ivermectin distribution scheme in Toro, Northern Nigeria. Public Health 1999, 113:193.
71. Pedersen E.M., Mukoko D.A. Impact of insecticide-treated materials on filaria transmission by the various species of vector mosquito in Africa. Ann. Trop. Med. Parasitol. 2002, 96:91.
72. Prost A., Prescott N. Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta. Bull. World Health Org. 1984, 62:795-802.
73. Rajendran R., Sunish I.P., Mani T.R., Munirathinam A., Abdullah S.M., Augustin D.J., Satyanarayana K. The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia. Ann. Trop. Med. Parasitol. 2002, 96:595-602.
74. Rakers L.J., Emukah E., Onyenama J., Amah G., Ukairo N., Enyinnaya U., Miri E., Richards F. Sustainability of ivermectin distribution programmes. Lancet 2009, 374:785-786.
75. Ramaiah K.D., Das P.K., Dhanda V. Estimation of permissible levels of transmission of bancroftian filariasis based on some entomological and parasitological results of a 5-year vector control programme. Acta Trop. 1994, 56:89-96.
76. Ramaiah K.D., Das P.K., Michael E., Guyatt H.L. The economic burden of lymphatic filariasis in India. Parasitol. Today 2000, 16:251-253.
77. Ramaiah K.D., Guyatt H., Ramu K., Vanamail P., Pani S.P., Das P.K. Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Trop. Med. Int. Health 1999, 4:19-25.
78. Ramaiah K.D., Ramu K., Guyatt H., Vijar Kumar K.N., Pani S.P. Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of Tamil Nadu, south India. Trop. Med. Int. Health 1998, 3:108-115.
79. Ramaiah K.D., Vijay Kumar K.N., Chandrakala A.V., Augustin D.J., Appavoo N.C., Das P.K. Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Trop. Med. Int. Health 2001, 6:1062-1069.
80. Ramaiah K.D., Vijay Kumar K.N., Hosein E., Krishnamoorthy P., Augustin D.J., Snehalatha K.S., Nanda B., Das P.K. A campaign of 'communication for behavioural impact' to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage. Ann. Trop. Med. Parasitol. 2006, 100:345-361.
81. Ramu K., Ramaiah K.D., Guyatt H., Evans D. Impact of lymphatic filariasis on the productivity of male weavers in a south Indian village. Trans. R. Soc. Trop. Med. Hyg. 1996, 90:669-670.
82. Ramzy R., Goldman A., Kamal H. Defining the cost of the Egyptian lymphatic filariasis elimination programme. Filaria J. 2005, 4:7.
83. Rao C.K., Chandrasekharan A., Cherian C. Frequency and duration of acute filarial attacks in persons in Brugia malayi endemic community. Indian J. Med. Res. 1982, 75:813-815.
84. Reimer L.J., Thomsen E.K., Tisch D.J., Henry-Halldin C.N., Zimmerman P.A., Baea M.E., Dagoro H., Susapu M., Hetzel M.W., Bockarie M.J., Michael E., Siba P.M., Kazura J.W. Insecticidal bed nets and filariasis transmission in Papua New Guinea. N. Engl. J. Med. 2013, 369:745-753.
85. Remme J.H.F., Feenstra P., Lever P.R., Medici A.C., Morel C.M., Noma M., Ramaiah K.D., Richards F., Seketeli A., Schmunis G., van Brakel W.H., Vassall A. Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. Disease Control Priorities in Developing Countries 2006, World Bank, Washington, DC. D.T. Jamison, J.G. Breman, A.R. Measham (Eds.).
86. Reuben R., Rajendran R., Sunish I.P., Mani T.R., Tewari S.C., Hiriyan J., Gajanana A. Annual single-dose diethylcarbamazine plus ivermectin for control of bancroftian filariasis: comparative efficacy with and without vector control. Ann. Trop. Med. Parasitol. 2001, 95:361-378.
87. Rheingans R., Haddix A., Messonnier M., Meltzer M., Mayard G., Addiss D. Willingness to pay for prevention and treatment of lymphatic filariasis in Leogane, Haiti. Filaria J. 2004, 3:2.
88. Richards F.O., Pam D.D., Kal A., Gerlong G.Y., Onyeka J., Sambo Y., Danboyi J., Ibrahim B., Terranella A., Kumbak D., Dakul A., Lenhart A., Rakers L., Umaru J., Amadiegwu S., Withers P.C., Mafuyai H., Jinadu M.Y., Miri E.S., Eigege A. Significant decrease in the prevalence of infection in anopheline mosquitoes following the addition of albendazole to annual, ivermectin-based, mass treatments in Nigeria. Ann. Trop. Med. Parasitol. 2005, 99:155-164.
89. Simonsen P.E. Filariases. Manson's Tropical Diseases 2009, Saunders Elsevier, China, 1477 pp. G.C. Cook, A.I. Zumla (Eds.).
90. TDR The Involvement of Community-Directed Distributors of Ivermectin in Other Health and Development Activities. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva 2003.
91. Tekle A.H., Zoure H., Wanji S., Leak S., Noma M., Remme J.H.F., Amazigo U. Integrated rapid mapping of onchocerciasis and loiasis in the Democratic Republic of Congo: impact on control strategies. Acta Trop. 2011, 120(Suppl. 1):S81-S90.
92. Thylefors B. The Mectizan Donation Program (MDP). Ann. Trop. Med. Parasitol. 2008, 102:39-44.
93. Wamae N., Njenga S.M., Kisingu W.M., Muthigani P.W., Kiiru K. Community-directed treatment of lymphatic filariasis in kenya and its role in the National Programmes for Elimination of Lymphatic Filariasis. Afr. J. Health Sci. 2006, 13:69-79.
94. Wanji S., Tendongfor N., Nji T., Esum M., Che J., Nkwescheu A., Alassa F., Kamnang G., Enyong P., Taylor M., Hoerauf A., Taylor D. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasit. Vectors 2009, 2:39.
95. Waters H.R., Rehwinkel J.A., Burnham G. Economic evaluation of Mectizan distribution. Trop. Med. Int. Health 2004, 9:A16-A25.
96. White M., Conteh L., Cibulskis R., Ghani A. Costs and cost-effectiveness of malaria control interventions - a systematic review. Malar. J. 2011, 10:337.
97. WHO Fact Sheet, 2013. Available at:. http://www.who.int/mediacenter/factsheets/FS102/En.
98. WHO Programmes, 2013. Available at:. http://www.who.int/apoc/onchocerciasis/status/en/.
99. Wijers D.J., Kinyanjui H. Bancroftian filariasis in Kenya. II. Clinical and parasitological investigations in Mambrui, a small coastal town, and Jaribuni, a rural area more inland (Coast Province). Ann. Trop. Med. Parasitol. 1977, 71:333-345.
100. World Bank and the Institute of Pathobiology, Addis Ababa University Health and Labor Productivity: The Economic Impact of Onchocercal Skin Disease 1997, World Bank, Africa Human Development Department, Onchocerciasis Coordination Unit.
101. Zhang Y., MacArthur C., Mubila L., Baker S. Control of neglected tropical diseases needs a long-term commitment. BMC Med. 2010, 8:67.